The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease.
Funding Type: Private company/industry
A Study of Donanemab in participants with early Alzheimer’s disease (TRAILBLAZER-ALZ 2)
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.
Training Primary Care Professionals in Motivational Interviewing
This project developed and delivered training and technical assistance in Motivational Interviewing for primary care professionals in OR state.
Training and Intensive Technical Assistance in Motivational Interviewing
This project offered training and intensive technical assistance in Motivational Interviewing for clinician members of a three-county provider association in OR state.
Training of Trainers Process in Screening, Brief Intervention, and Referral to Treatment
This project offered a training of trainers process in SBIRT for personnel of a healthcare organization in King County.
Rural Mental Health Integration Initiative (RMHII)
The RMHII is a partnership between the AIMS Center and Premera Blue Cross to expand access to evidence-based mental health treatment in rural areas. The AIMS Center will lead clinic selection, training, technical assistance, and practice coaching for up to 30 primary care clinics in rural Washington and Alaska.
Clinical study of cannabidiol in children and adolescents with Fragile X (CONNECT-FX) & Open-Label Extension (CONNECT-FX OLE)
To evaluate the efficacy of ZYN002 administered as a transdermal gel formulation, for up to 12 weeks, in patients ages 3 to <18 years, in the treatment of symptoms of Fragile X Syndrome (FXS).
